From JANUVIA to MARIZEV (Omarigliptin), a once weekly DPP-4 inhibitor for the treatment of diabetes

被引：0
|
作者：
Weber, Ann [1 ]
机构：
[1] Kallyope Inc, New York, NY USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2018年 / 255卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
15
引用
收藏
页数：1
相关论文
共 50 条
  • [1] MK-3102 (omarigliptin): A novel DPP-4 inhibitor for once weekly treatment of type 2 diabetes
    Biftu, Tesfaye
    Chen, Ping
    Qian, Xiaoxia
    Feng, Dennis
    Cox, Jason
    Hicks, Jacqueline
    Sinha-Roy, Ranabir
    Scapin, Giovanna
    Gao, Ying-Duo
    Eiermann, George
    He, Jiafang
    He, Huaibing
    Kuethe, Jeffery
    Lyons, Kathy
    Salituro, Gino
    Patel, Sangita
    Petrov, Aleksandr
    Wu, Joseph
    Zhang, Xiaoping
    Zhang, Bei
    Weber, Ann
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 246
  • [2] Once-Weekly Treatment with Omarigliptin, a DPP-4 Inhibitor, Improves Glycemic Control in Patients Not at Goal on Metformin
    Shankar, R. Ravi
    Inzucchi, Silvio E.
    Gantz, Ira
    O'Neill, Edward A.
    Scarabello, Victoria
    Ceesay, Paulette
    Suryawanshi, Shailaja
    Lai, Eseng
    DIABETES, 2016, 65 : A293 - A293
  • [3] Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes
    Biftu, Tesfaye
    Sinha-Roy, Ranabir
    Chen, Ping
    Qian, Xiaoxia
    Feng, Dennis
    Kuethe, Jeffrey T.
    Scapin, Giovanna
    Gao, Ying Duo
    Tan, Youwei
    Krueger, Davida
    Bak, Annette
    Eiermann, George
    He, Jiafang
    Cox, Jason
    Hicks, Jacqueline
    Lyons, Kathy
    He, Huaibing
    Salituro, Gino
    Tong, Sharon
    Patel, Sangita
    Doss, George
    Petrov, Aleksandr
    Wu, Joseph
    Xu, Shiyao Sherrie
    Sewall, Charles
    Zhang, Xiaoping
    Zhang, Bei
    Thornberry, Nancy A.
    Weber, Ann E.
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (08) : 3205 - 3212
  • [4] Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes
    Sheu, Wayne H. -H.
    Gantz, Ira
    Chen, Menghui
    Suryawanshi, Shailaja
    Mirza, Arpana
    Goldstein, Barry J.
    Kaufman, Keith D.
    Engel, Samuel S.
    DIABETES CARE, 2015, 38 (11) : 2106 - 2114
  • [5] Absorption, Metabolism, and Excretion of [14C] Omarigliptin, a Once-Weekly DPP-4 Inhibitor, in Humans
    Xu, Shiyao
    Kauh, Anya
    Tatosian, Daniel
    Mcintosh, Ian
    Caceres, Maria
    Matthews, Catherine
    Miller, Jutta
    Kumar, Sanjeev
    Wirth, Mark
    DIABETES, 2014, 63 : A281 - A281
  • [6] Absorption, metabolism and excretion of [14C]omarigliptin, a once-weekly DPP-4 inhibitor, in humans
    Xu, Shiyao
    Tatosian, Dan
    Mcintosh, Ian
    Caceres, Maria
    Matthews, Catherine
    Samuel, Koppara
    Selverian, Diana
    Kumar, Sanjeev
    Kauh, Eunkyung
    XENOBIOTICA, 2018, 48 (06) : 584 - 591
  • [7] A NOVEL ONCE-WEEKLY DPP-4 INHIBITOR IN THE CARE OF TYPE 2 DIABETES
    Grigorescu, Elena-Daniela Dediu
    MEDICAL-SURGICAL JOURNAL-REVISTA MEDICO-CHIRURGICALA, 2016, 120 (03): : 603 - 603
  • [8] Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy
    Goldenberg, Ronald
    Gantz, Ira
    Andryuk, Paula J.
    O'Neill, Edward A.
    Kaufman, Keith D.
    Lai, Eseng
    Wang, Yin Na
    Suryawanshi, Shailaja
    Engel, Samuel S.
    DIABETES OBESITY & METABOLISM, 2017, 19 (03): : 394 - 400
  • [9] A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus
    Gantz, Ira
    Chen, Menghui
    Suryawanshi, Shailaja
    Ntabadde, Catherine
    Shah, Sukrut
    O'Neill, Edward A.
    Engel, Samuel S.
    Kaufman, Keith D.
    Lai, Eseng
    CARDIOVASCULAR DIABETOLOGY, 2017, 16
  • [10] First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus
    Kaku, Kohei
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (16) : 2539 - 2547
12345